期刊文献+

Earlier application of loading doses of aspirin and clopidogrel decreases rate of recurrent cardiovascular ischemic events for patients undergoing percutaneous coronary intervention 被引量:13

Earlier application of loading doses of aspirin and clopidogrel decreases rate of recurrent cardiovascular ischemic events for patients undergoing percutaneous coronary intervention
原文传递
导出
摘要 Background Aspirin and clopidogrel resistance plays a significant role in the development of cardiovascular ischemic events for ninety patients undergoing percutaneous coronary intervention.Recent studies have indicated that increasing the dose of antiplatelet drugs maybe a potent method to improve the inhibition of platelet aggregation.Methods Thrombelastograph (TEG) determinations were used to evaluate the effect of antiplatelet therapy.According to the results,90 patients were divided into three groups and given different doses of aspirin and clopidogrel.Thirty patients with both an inhibition rate of aspirin 〉50% and an inhibition rate of clopidogrel 〉50% were defined as the control group.Sixty patients with an inhibition rate for aspirin 〈50% and an inhibition rate for clopidogrel 〈50% were defined as the resistance group.Patients in resistance group were randomly assigned to be given a routine dose (100 mg aspirin plus 75 mg clopidogrel per day,which we called a resistance plus routine dose group,R+R) and a loading dose (200 mg aspirin and 150 mg clopidogrel per day,which we called resistance plus loading dose group,R+L) of antiplatelet therapy.A 12-month follow-up was observed to examine the change of inhibition rate of antiplatelet therapy and to estimate the relationship between inhibition rate and the occurrence of cardiovascular ischemic events.Results After 6 months of antiplatelet therapy,the inhibition rate of aspirin in the R+L group increased from (31.4±3.7)% to (68.6±7.1)%,which was significantly higher than that in R+R group,(51.9±8.2)% (P 〈0.01).The inhibition rate of clopidogrel in the R+L group increased from (22.1±3.8)% to (60.2±7.4)%,which was significantly higher than in the R+R group,(45.9±4.3)% (P 〈0.01).The occurrence rates of cardiovascular ischemic events,stent thrombosis,recurrent unstable angina and myocardial infarction in the R+R group were 20%,36% and 17%,respectively.Occurrence was significantly increased compared with that in the control group,3%,10% and 1%,respectively (P 〈0.01).In contrast,the occurrence rates in the R+L group (10%,23% and 6%,respectively) were attenuated compared with those in the R+R group (P 〈0.01 ),although still higher than in the control group (P 〈0.01).Conclusions Almost all of the cardiovascular ischemic events occurred in the first six months after percutaneous coronary intervention.According to the result of TEG determinations,earlier application of a loading dose of aspirin and clopidogrel can decrease the rate of recurrent cardiovascular ischemic events. Background Aspirin and clopidogrel resistance plays a significant role in the development of cardiovascular ischemic events for ninety patients undergoing percutaneous coronary intervention.Recent studies have indicated that increasing the dose of antiplatelet drugs maybe a potent method to improve the inhibition of platelet aggregation.Methods Thrombelastograph (TEG) determinations were used to evaluate the effect of antiplatelet therapy.According to the results,90 patients were divided into three groups and given different doses of aspirin and clopidogrel.Thirty patients with both an inhibition rate of aspirin 〉50% and an inhibition rate of clopidogrel 〉50% were defined as the control group.Sixty patients with an inhibition rate for aspirin 〈50% and an inhibition rate for clopidogrel 〈50% were defined as the resistance group.Patients in resistance group were randomly assigned to be given a routine dose (100 mg aspirin plus 75 mg clopidogrel per day,which we called a resistance plus routine dose group,R+R) and a loading dose (200 mg aspirin and 150 mg clopidogrel per day,which we called resistance plus loading dose group,R+L) of antiplatelet therapy.A 12-month follow-up was observed to examine the change of inhibition rate of antiplatelet therapy and to estimate the relationship between inhibition rate and the occurrence of cardiovascular ischemic events.Results After 6 months of antiplatelet therapy,the inhibition rate of aspirin in the R+L group increased from (31.4±3.7)% to (68.6±7.1)%,which was significantly higher than that in R+R group,(51.9±8.2)% (P 〈0.01).The inhibition rate of clopidogrel in the R+L group increased from (22.1±3.8)% to (60.2±7.4)%,which was significantly higher than in the R+R group,(45.9±4.3)% (P 〈0.01).The occurrence rates of cardiovascular ischemic events,stent thrombosis,recurrent unstable angina and myocardial infarction in the R+R group were 20%,36% and 17%,respectively.Occurrence was significantly increased compared with that in the control group,3%,10% and 1%,respectively (P 〈0.01).In contrast,the occurrence rates in the R+L group (10%,23% and 6%,respectively) were attenuated compared with those in the R+R group (P 〈0.01 ),although still higher than in the control group (P 〈0.01).Conclusions Almost all of the cardiovascular ischemic events occurred in the first six months after percutaneous coronary intervention.According to the result of TEG determinations,earlier application of a loading dose of aspirin and clopidogrel can decrease the rate of recurrent cardiovascular ischemic events.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2012年第4期631-638,共8页 中华医学杂志(英文版)
关键词 aspirin resistance clopidogrel resistance thrombelastograph percutaneous coronary intervention cardiovascular ischemic events aspirin resistance clopidogrel resistance thrombelastograph percutaneous coronary intervention cardiovascular ischemic events
  • 相关文献

参考文献33

  • 1Gurbel PA,Tantry US.Aspirin and clopidogrel resistance:consideration and management.J Interv Cardiol 2006; 19:439-448.
  • 2Cutlip DE,Baim DS,Ho KK,Popma JJ,Lansky AJ,Cohen DJ,et al.Stent thrombosis in the modern era:a pooled analysis of multicenter coronary stent clinical trials.Circulation 2001; 103:1967-1971.
  • 3Orford JL,Lennon R,Melby S,Fasseas P,Bell MR,Rihal CS,et al.Frequency and correlates of coronary stent thrombosis in the modem era:analysis of a single center registry.J Am Coll Cardiol 2002; 40:1567-1572.
  • 4Takahashi S,Kaneda H,Tanaka S,Miyashita Y,Shiono T,Taketani Y,et al.Late angiographic stent thrombosis after sirolimus-eluting stent implantation.Circ J 2007; 71:226-228.
  • 5Biondi-Zoccai GG,Agostoni P,Sangiorgi GM,Iakovou I,Antoniucci D,Grube E,et al.TRUE (Taxus in Real-Life Usage Evaluation) Study Investigators.Comparison of ticlopidine vs.clopidogrel in addition to aspirin after paclitaxel-eluting stent implantation:insights from the TRUE (Taxusin Real-life Usage Evaluation) Study.Int J Cardiol 2006; 108:406-407.
  • 6Barragan P,Bouvier JL,Roquebert PO,Macaluso G,Commeau P,Comet B,et al.Resistance to thienopyridines:clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation.Catheter Cardiovasc Interv 2003; 59:295-302.
  • 7Matetzky S,Shenkman B,Guetta V,Shechter M,Bienart R,Goldenberg I,et al.Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.Circulation 2004; 109:3171-3175.
  • 8Cuisset T,Frere C,Quilici J,Barbou F,Morange PE,Hovasse T,et al.High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome.J Thromb Haemost 2006; 4:542-549.
  • 9Bonello L,Camoin-Jau L,Arques S,Boyer C,Panagides D,Wittenberg O,et al.Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance.J Am Coll Cardiol 2008; 51:1404-1411.
  • 10Shim CY,Yoon SJ,Park S,Kim JS,Choi JR,Ko YG,et al.The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation.Int J Cardiol 2009; 134:351-355.

同被引文献60

引证文献13

二级引证文献95

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部